Serial ESR1 Mutation Monitoring Market is estimated to be valued at USD 286.4 Mn in 2026 and is expected to reach USD 645.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 12.3% from 2026 to 2033.
| Report Coverage |
Report Details |
| Base Year: |
2025 |
Market Size in 2026: |
USD 286.4 Mn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: |
12.30% |
2033 Value Projection: |
USD 645.8 Mn |
The global serial ESR1 mutation monitoring market is a dedicated segment in the category of cancer screening, and liquid biopsy testing. The market is specifically centered on the identification and monitoring of ESR1 mutations in patients with HR+ HER2- advanced breast cancers, which can evolve during endocrine therapy and might result in resistance to treatment, prompting the need for serial monitoring to determine molecular changes.
Advances in circulating tumor DNA (ctDNA) testing, next-generation sequencing (NGS), digital PCR and droplet digital PCR (ddPCR) are making it easier to detect ESR1 mutations in blood tests. Growing focus on personalized oncology, early recognition of resistance, and molecularly-directed treatment selection by diagnostic laboratories, healthcare providers, and oncology stakeholders is buoying increasing interest in serial ESR1 monitoring.
Market Dynamics
The global serial ESR1 mutation monitoring market is driven by the rising need to detect endocrine therapy resistance in hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. In addition, increasing uptake of liquid biopsy and circulating tumor DNA (ctDNA) testing along with clinical validation for ESR1 mutation-guided treatment selection and progress in targeted therapies will add to the growing need for robust molecular diagnostics solution that can lead to a treatment decision in no time.
However, a number of constraints are present in the market, such as high testing costs, inconsistent assay standardization, differences in analytical sensitivity, and limited reimbursement access particularly in emerging markets. Nevertheless, significant opportunities exist in linking AI genomic analytics with greater access to liquid biopsy tests and fostering ties between pharma developers and diagnostic firms to further validate companion diagnostics and personalized cancer treatment.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global serial ESR1 mutation monitoring market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Guardant Health, Inc., Foundation Medicine, Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., QIAGEN N.V., NeoGenomics Laboratories, Inc., Roche Diagnostics, Sysmex Corporation, Tempus AI, Inc., and GENCURIX, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global serial ESR1 mutation monitoring market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global serial ESR1 mutation monitoring market
Market Segmentation
- Testing Technology Insights (Revenue, USD Mn, 2021 - 2033)
- Next-Generation Sequencing (NGS)
- PCR-Based Assays
- Digital Droplet PCR (ddPCR)
- Sample Type Insights (Revenue, USD Mn, 2021 - 2033)
- Plasma
- Serum
- Other Blood-Derived Samples
- Monitoring Approach Insights (Revenue, USD Mn, 2021 - 2033)
- Baseline ESR1 Mutation Testing
- Serial ctDNA Monitoring During Treatment
- Testing at Disease Progression
- Application Insights (Revenue, USD Mn, 2021 - 2033)
- Detection of Endocrine Therapy Resistance
- Treatment Selection and Modification
- Monitoring of Emerging ESR1 Mutations
- End User Insights (Revenue, USD Mn, 2021 - 2033)
- Hospitals and Oncology Clinics
- Diagnostic and Reference Laboratories
- Cancer Research and Academic Institutes
- Others
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Guardant Health, Inc.
- Foundation Medicine, Inc.
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories, Inc.
- QIAGEN N.V.
- NeoGenomics Laboratories, Inc.
- Roche Diagnostics
- Sysmex Corporation
- Tempus AI, Inc.
- GENCURIX, Inc.